Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

January 3, 2025

By Al-Ola Abdallah, MD
Muhammad Umair Mushtaq, MD

Opinion

Video

Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.

EP: 1.Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

Now Viewing

EP: 2.Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?

EP: 3.Selecting Between the Currently Available CAR-T Therapies for R/R MM: Patient Considerations and Criteria

EP: 4.University of Kansas Medical Center Insights: CAR T Referral Process

EP: 5.Reviewing CAR T Mechanism & Treatment Process

EP: 6.Approaches to Bridging Therapy During the CAR T Manufacturing Process

EP: 7.Comanaging Cases of RR/MM in Patients Receiving CAR T

EP: 8.On-going Clinical Trials With CAR T Therapy in Earlier-Line Multiple Myeloma Treatment: Future Perspectives

EP: 9.Expert Insights: 68yM High-Risk R/R MM Post HSCT With Progressive Disease—Next Steps?

EP: 10.Expert Insights: Key Takeaways & Clinical Pearls on CAR T Therapy in R/R MM

Video content above is prompted by the following:

How does the issue of slot availability for chimeric antigen receptor (CAR) T-cell therapy, along with the waiting list, fit into the ongoing challenges faced at the institutional level?
Dr Abdallah to ask Dr Mushtaq: If you choose to use CAR T-cell therapy in earlier lines of therapy, what might you do next and why?

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!